174 related articles for article (PubMed ID: 22333896)
1. From bench-to-bedside in catastrophic cerebrovascular disease: development of drugs targeting the endothelin axis in subarachnoid hemorrhage-related vasospasm.
Ardelt A
Neurol Res; 2012 Mar; 34(2):195-210. PubMed ID: 22333896
[TBL] [Abstract][Full Text] [Related]
2. Clazosentan, an endothelin receptor antagonist, prevents early hypoperfusion during the acute phase of massive experimental subarachnoid hemorrhage: a laser Doppler flowmetry study in rats.
Schubert GA; Schilling L; Thomé C
J Neurosurg; 2008 Dec; 109(6):1134-40. PubMed ID: 19035733
[TBL] [Abstract][Full Text] [Related]
3. MEK1/2 inhibitor U0126 but not endothelin receptor antagonist clazosentan reduces upregulation of cerebrovascular contractile receptors and delayed cerebral ischemia, and improves outcome after subarachnoid hemorrhage in rats.
Povlsen GK; Edvinsson L
J Cereb Blood Flow Metab; 2015 Feb; 35(2):329-37. PubMed ID: 25407271
[TBL] [Abstract][Full Text] [Related]
4. Effect of endothelin-receptor antagonists on delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage remains unclear.
Vergouwen MD
Stroke; 2009 Dec; 40(12):e714; author reply e715-6. PubMed ID: 19875735
[No Abstract] [Full Text] [Related]
5. Clazosentan (AXV-034343), a selective endothelin A receptor antagonist, in the prevention of cerebral vasospasm following severe aneurysmal subarachnoid hemorrhage: results of a randomized, double-blind, placebo-controlled, multicenter phase IIa study.
Vajkoczy P; Meyer B; Weidauer S; Raabe A; Thome C; Ringel F; Breu V; Schmiedek P
J Neurosurg; 2005 Jul; 103(1):9-17. PubMed ID: 16121967
[TBL] [Abstract][Full Text] [Related]
6. Clazosentan: an endothelin receptor antagonist for treatment of vasospasm after subarachnoid hemorrhage.
Macdonald RL
Expert Opin Investig Drugs; 2008 Nov; 17(11):1761-7. PubMed ID: 18922111
[TBL] [Abstract][Full Text] [Related]
7. Thick and Diffuse Subarachnoid Blood as a Treatment Effect Modifier of Clazosentan After Subarachnoid Hemorrhage.
Mayer SA; Aldrich EF; Bruder N; Hmissi A; Macdonald RL; Viarasilpa T; Marr A; Roux S; Higashida RT
Stroke; 2019 Oct; 50(10):2738-2744. PubMed ID: 31394993
[TBL] [Abstract][Full Text] [Related]
8. Microvasospasms After Experimental Subarachnoid Hemorrhage Do Not Depend on Endothelin A Receptors.
Liu H; Dienel A; Schöller K; Schwarzmaier SM; Nehrkorn K; Plesnila N; Terpolilli NA
Stroke; 2018 Mar; 49(3):693-699. PubMed ID: 29438081
[TBL] [Abstract][Full Text] [Related]
9. Dissociation of vasospasm-related morbidity and outcomes in patients with aneurysmal subarachnoid hemorrhage treated with clazosentan: a meta-analysis of randomized controlled trials.
Shen J; Pan JW; Fan ZX; Xiong XX; Zhan RY
J Neurosurg; 2013 Jul; 119(1):180-9. PubMed ID: 23641823
[TBL] [Abstract][Full Text] [Related]
10. Effect of delayed cerebral vasospasm on cerebrovascular endothelin A receptor expression and function.
Vatter H; Konczalla J; Weidauer S; Preibisch C; Zimmermann M; Raabe A; Seifert V
J Neurosurg; 2007 Jul; 107(1):121-7. PubMed ID: 17639881
[TBL] [Abstract][Full Text] [Related]
11. Novel treatments for vasospasm after subarachnoid hemorrhage.
Muroi C; Seule M; Mishima K; Keller E
Curr Opin Crit Care; 2012 Apr; 18(2):119-26. PubMed ID: 22234053
[TBL] [Abstract][Full Text] [Related]
12. Endothelin receptor antagonists for aneurysmal subarachnoid hemorrhage: a systematic review and meta-analysis update.
Vergouwen MD; Algra A; Rinkel GJ
Stroke; 2012 Oct; 43(10):2671-6. PubMed ID: 22871682
[TBL] [Abstract][Full Text] [Related]
13. Randomised trial of clazosentan, an endothelin receptor antagonist, in patients with aneurysmal subarachnoid hemorrhage undergoing surgical clipping (CONSCIOUS-2).
Macdonald RL; Higashida RT; Keller E; Mayer SA; Molyneux A; Raabe A; Vajkoczy P; Wanke I; Bach D; Frey A; Marr A; Roux S; Kassell N
Acta Neurochir Suppl; 2013; 115():27-31. PubMed ID: 22890639
[TBL] [Abstract][Full Text] [Related]
14. Endothelin receptor antagonists for subarachnoid hemorrhage.
Guo J; Shi Z; Yang K; Tian JH; Jiang L
Cochrane Database Syst Rev; 2012 Sep; (9):CD008354. PubMed ID: 22972119
[TBL] [Abstract][Full Text] [Related]
15. Preventing vasospasm improves outcome after aneurysmal subarachnoid hemorrhage: rationale and design of CONSCIOUS-2 and CONSCIOUS-3 trials.
Macdonald RL; Higashida RT; Keller E; Mayer SA; Molyneux A; Raabe A; Vajkoczy P; Wanke I; Frey A; Marr A; Roux S; Kassell NF
Neurocrit Care; 2010 Dec; 13(3):416-24. PubMed ID: 20838933
[TBL] [Abstract][Full Text] [Related]
16. Dissociation of vasospasm and secondary effects of experimental subarachnoid hemorrhage by clazosentan.
Sabri M; Ai J; Macdonald RL
Stroke; 2011 May; 42(5):1454-60. PubMed ID: 21454820
[TBL] [Abstract][Full Text] [Related]
17. Effects of the selective endothelin A (ET(A)) receptor antagonist Clazosentan on cerebral perfusion and cerebral oxygenation following severe subarachnoid hemorrhage - preliminary results from a randomized clinical series.
Barth M; Capelle HH; Münch E; Thomé C; Fiedler F; Schmiedek P; Vajkoczy P
Acta Neurochir (Wien); 2007; 149(9):911-8; discussion 918. PubMed ID: 17700991
[TBL] [Abstract][Full Text] [Related]
18. Electrocardiographic changes predict angiographic vasospasm after aneurysmal subarachnoid hemorrhage.
Ibrahim GM; Macdonald RL
Stroke; 2012 Aug; 43(8):2102-7. PubMed ID: 22678087
[TBL] [Abstract][Full Text] [Related]
19. Vasospasm after aneurysmal subarachnoid hemorrhage: need for further study.
Pearl JD; Macdonald RL
Acta Neurochir Suppl; 2008; 105():207-10. PubMed ID: 19066110
[TBL] [Abstract][Full Text] [Related]
20. Clazosentan, an endothelin receptor antagonist, in patients with aneurysmal subarachnoid haemorrhage undergoing surgical clipping: a randomised, double-blind, placebo-controlled phase 3 trial (CONSCIOUS-2).
Macdonald RL; Higashida RT; Keller E; Mayer SA; Molyneux A; Raabe A; Vajkoczy P; Wanke I; Bach D; Frey A; Marr A; Roux S; Kassell N
Lancet Neurol; 2011 Jul; 10(7):618-25. PubMed ID: 21640651
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
